BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

BCR-ABL TKIs are the standard-of-care treatment for chronic myelogenous leukemia (CML). While several side-effects of these TKIs are well-known or included on the FDA label, renal adverse drug reactions are not. We recently observed 2 patients with proteinuria and acute kidney injury (AKI) not attri...

Full description

Bibliographic Details
Main Authors: Michele Stanchina, Zoe McKinnell, Jae H. Park, Eytan M. Stein, Sheng F. Cai, Justin Taylor
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Leukemia Research Reports
Subjects:
Imatinib
Dasatinib
Nilotinib
Ponatinib
Bcr-abl
Chronic myeloid leukemia
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048920300170

Internet

http://www.sciencedirect.com/science/article/pii/S2213048920300170

Similar Items